Business
Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update
Alpha Cognition generated fourth quarter 2025 ZUNVEYL net product revenue of $2.5 million, contributing to full year 2025 total revenue of $10.2 million
About this update from Alpha Cognition Inc.
[{"type":"text","content":"\nAlpha Cognition generated fourth quarter 2025 ZUNVEYL net product revenue of $2.5 million, contributing to full year 2025 total revenue of $10.2 million\n\n\nFourth quarter bottles dispensed increased 62% quarter-over-quarter to 4,941, with December representing the strongest month since launch\n\n\nExecuted second national PBM contract and initiating three studies to further support ZUNVEYL’s positioning in long-term care Alzheimer’s patients\n\n\nCash and cash equivalents totaled $66 million at year-end 2025, supporting the company’s continued target of operating profitability in 2027\n\n\nCompany to host conference call and webcast today, March 26, at 4:30 p.m. ET\n\n\n VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--\nAlpha Cognition Inc. (ACOG: NASDAQ) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.\n\n\n“2025 was a year of strong commercial execution for Alpha Cognition as we continued to build momentum for ZUNVEYL – the first new oral Alzheimer’s treatment approved in more than 15 years. In the fourth quarter, we saw strong growth in demand, with December representing our strongest month since launch. We’re encouraged by the increasing rates of repeat ordering, indicating ZUNVEYL is moving beyond initial trial and becoming increasingly integrated into routine management in long-term care,” said Michael McFadden, Chief Executive Officer of Alpha Cognition.\n\n\n“Importantly, we also executed a second national PBM contract, bringing us to two of the four major PBMs relevant to long-term care. Combined with the consistent clinical feedback we’re hearing on ZUNVEYL’s tolerability and behavioral profile, we believe we are well positioned to continue driving adoption as payer pull-through improves in 2026. We enter the year well-capitalized and focused on expanding our commercial footprint, deepening prescriber engagement, and advancing toward operational profitability in 2027.”\n\n\nZUNVEYL Commercial Performance\n\n\n\nNet ZUNVEYL Revenue: Generated approximately $2.5 million in net product revenue in the fourth quarter of 2025. Launch-to-date net product revenue through year-end 20...